文献速递肿瘤 PET/CT

抗坏血酸类似物6-脱氧-6-[18F]氟-L-抗坏血酸PET显像在癌症患者中的生物分布与辐射剂量学:首次人体研究

Biodistribution and radiation dosimetry in cancer patients of the ascorbic acid analogue 6-Deoxy-6-[18F] fluoro-L-ascorbic acid PET imaging: first-in-human study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-05-16

该首次人体研究纳入6例多种癌症患者,注射313-634 MBq的[18F]DFA后行全身PET/CT及5次动态扫描(5-60分钟),评估其分布、肿瘤检出能力与辐射剂量学。结果显示[18F]DFA耐受良好、无严重不良事件,肿瘤摄取快速且靶本比随时间升高,平均有效剂量为1.68±0.36 E-02 mSv/MBq。

要点

  • [18F]DFA在人体内安全耐受,6例受试者均未出现严重不良事件。
  • 肿瘤病灶平均SUVmax为6.94±3.92(范围1.62-22.85,中位数5.94),靶本比随时间升高。
  • 平均有效剂量估计为1.68±0.36 E-02 mSv/MBq。

核心结论

  • [18F]DFA可安全用于人体,分布模式与抗坏血酸相似,在肿瘤中显示高摄取和滞留且动力学适当。
  • [18F]DFA可能是识别对SVCT2高亲和力肿瘤及监测抗坏血酸在正常组织和肿瘤中分布的有前景的放射性药物。

研究设计与样本

  • 首次人体PET显像研究,纳入6例多种癌症患者。
  • 每例患者注射313-634 MBq的[18F]DFA后行全身PET/CT,并在5-60分钟采集5次连续动态发射扫描。
  • 勾画源器官和肿瘤横断面PET图像边缘的兴趣区,用肿瘤SUVmax与背景SUVmean计算靶本比。
  • 通过时间-放射性曲线计算器官滞留时间,并采用医学内照射剂量方法估算人体吸收剂量。

主要发现

  • [18F]DFA在所有受试者中耐受良好,无严重不良事件。
  • 肝脏、肾上腺、肾脏、脉络丛和垂体可见高摄取。
  • [18F]DFA在肿瘤中快速聚集,靶本比随时间升高。
  • 肿瘤病灶[18F]DFA平均SUVmax为6.94±3.92(范围1.62-22.85,中位数5.94)。
  • 吸收剂量最高的器官为肝脏、脾脏、肾上腺和肾脏,平均有效剂量估计为1.68±0.36 E-02 mSv/MBq。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clinical studies on the use of ascorbic acid (AA) have become a hot spot in cancer research. There remains an unmet need to assess AA utilization in normal tissues and tumors. 6-Deoxy-6-[18F]fluoro-L-ascorbic acid ([18F]DFA) displayed distinctive tumor localization and similar distribution as AA in mice. In this study, to evaluate the distribution, tumor detecting ability and radiation dosimetry of [18F]DFA in humans, we performed the first-in-human PET imaging study. METHODS: Six patients with a variety of cancers underwent whole-body PET/CT scans after injection of 313-634 MBq of [18F]DFA. Five sequential dynamic emission scans in each patient were acquired at 5-60 min. Regions of interest (ROI) were delineated along the edge of the source-organ and tumor on the transverse PET slice. Tumor-to-background ratio (TBR) was obtained using the tumor SUVmax to background SUVmean. Organ residence times were calculated via time-activity curves, and human absorbed doses were estimated from organ residence time using the medical internal radiation dosimetry method. RESULTS: [18F]DFA was well tolerated in all subjects without serious adverse event. The high uptake was found in the liver, adrenal glands, kidneys, choroid plexus, and pituitary gland. [18F]DFA accumulated in tumor rapidly and the TBR increased over time. The average SUVmax of [18F]DFA in tumor lesions was 6.94 ± 3.92 (range 1.62-22.85, median 5.94). The organs with the highest absorbed doses were the liver, spleen, adrenal glands, and kidneys. The mean effective dose was estimated to be 1.68 ± 0.36 E-02 mSv/MBq. CONCLUSIONS: [18F]DFA is safe to be used in humans. It showed a similar distribution pattern as AA, and displayed high uptake and retention in tumors with appropriate kinetics. [18F]DFA might be a promising radiopharmaceutical in identifying tumors with high affinity for SVCT2 and monitoring AA distribution in both normal tissues and tumors. TRIAL REGISTRATION: Chinese Clinical Trial Registry; Registered Number: ChiCTR2200057842 (registered 19 March 2022).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Long Y, Yi C, Wu R, et al. Biodistribution and radiation dosimetry in cancer patients of the ascorbic acid analogue 6-Deoxy-6-[18F] fluoro-L-ascorbic acid PET imaging: first-in-human study. Eur J Nucl Med Mol Imaging. 2023. PMID: 37191679. doi:10.1007/s00259-023-06262-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。